OpenAI May Delay IPO to 2027 Amid $1 Trillion Valuation Goal 
Trump Requests $11 Billion More in Farm Aid as Rising Costs Pressure U.S. Farmers 
Samsung and SK Hynix Shares Jump After Micron Earnings Boost AI Chip Optimism 
US Dollar Climbs to One-Year High as Fed Rate Hike Expectations Surge 
Samsung Electronics Stock Surges on Report of Massive $59 Billion Share Buyback Plan 
South Korea Remains MSCI Emerging Market Despite Reform Progress 
Alibaba Shares Fall After Anthropic Alleges Massive AI Model Distillation Campaign 
WiseTech Global Denies Knowledge of Investigation Into Founder Richard White 
US Dollar Slips After PCE Inflation Data Eases Fed Rate Hike Expectations 
South Korea’s KOSPI Rebounds as Samsung and SK Hynix Lead Tech Stock Recovery 
Wall Street Ends Mixed as Tech Stocks Struggle Ahead of Micron Earnings 
Pelosi Discloses Major Intel and Uber Call Option Purchases Worth Up to $6 Million 
Trump Orders DOJ Investigation Into Exxon, Chevron Over High Gas Prices 
Kioxia Targets U.S. Listing as AI Chip Boom Accelerates 
Wall Street Ends Mixed as Micron Surges, Apple Drops After Price Hikes 
Australia Jobs Growth Strengthens Rate Hike Outlook 
Nissan Halts Electric Qashqai Development Amid EV Market Challenges 
Eli Lilly gets a subpoena from the U.S. Department of Justice with regards to its manufacturing factory in New Jersey that produces COVID-19 treatment called bamlanivimab. Based on the report, the DOJ wants the pharmaceutical company to forward some documents.
As per Reuters, while it was not specified what documents are being requested by the officials, they are something related to Eli Lilly’s factory site in Branchburg, New Jersey. The company said that it is actively participating and fully cooperating with the investigation.
The issue with Eli Lilly’s NJ plant
Earlier this month, some of Eli Lilly’s employees alleged that an executive in the NJ plant altered the documents so it can pass quality control without a problem. The papers are required by regulators for the operation of the company’s factory, but with the modification, the employees feared it would cause serious quality control issues.
It was relayed that in November 2019, inspectors from the U.S. Food and Drug Administration were sent over to check Eli Lilly’s Branchburg factory. They discovered that much of the data related to manufacturing processes were deleted while others were not inappropriately audited.
The pharmaceutical company is also said to be facing issues with its quality control and production at its plant in Indianapolis. This is the site where bamlanivimab and other medicines are being bottled.
Lilly conducting its own internal probe
As per Financial Post, Eli Lilly also launched its own investigation concerning the allegations. The company also hired counsel who will carry out an independent probe in its New Jersey facility.
“Lilly is deeply committed to manufacturing high-quality medicines for patients who need them, and the safety and quality of our products is our highest priority,” the firm stated.
In any case, while the investigation is ongoing, Eli Lilly published the subpoena issued to them by the DOJ. This move shows that the company is being transparent with the investigation and doing its best to resolve the problems too. Meanwhile, the company could not comment further on the case as of this time since a conclusion has not been reached yet.
